Literature DB >> 25138650

Circadian variation of mineral and bone parameters in end-stage renal disease.

Hariprasad Trivedi1, Aniko Szabo, Shi Zhao, Tom Cantor, Hershel Raff.   

Abstract

BACKGROUND: Mineral and bone parameters are actively managed in end-stage renal disease (ESRD). However, whether these undergo circadian variation is not known. We investigated the circadian variation of mineral and bone parameters in patients on long-term hemodialysis.
METHODS: Seventeen ESRD patients on long-term hemodialysis and eight volunteers without kidney disease were enrolled. Subjects had all medications that affect calcium-phosphate-parathyroid hormone balance (phosphate binders, vitamin D analogues, and calcimimetics) discontinued. Thereafter, for a period of 5 days, subjects consumed a diet controlled in calcium (1,200 mg per day) and phosphorus (1,000 mg per day) content. On the sixth day (a non-dialysis day for the ESRD patients), enrollees underwent twelve 2-h blood draws for phosphate, ionized calcium, parathyroid hormone (PTH), total 25-hydroxy vitamin D (25OHD), and fibroblast growth factor-23 (FGF-23).
RESULTS: In the ESRD patients plasma phosphate demonstrated significant circadian variation (P < 0.00001). The peak occurred around 3:30 am and nadir occurred around 11:00 am. Ionized calcium (P = 0.0036), PTH (P = 0.0004) and 25OHD (P = 0.009) also varied significantly during the circadian period; for ionized calcium peak and nadir occurred around 12:15 pm and 8:00 pm, parathyroid hormone 5:45 pm and 10:15 am, and 25OHD 9:45 am and 4:00 pm respectively. FGF-23 did not show a significant circadian variation. Only phosphate (P < 0.0001) and PTH (P = 0.00008) demonstrated circadian variation in the control group.
CONCLUSIONS: Blood concentrations of phosphate, calcium, PTH and 25-hydroxy vitamin D, exhibit a circadian variation in patients with ESRD. Knowledge of these phenomena is pertinent for the interpretation of clinical testing.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25138650      PMCID: PMC4663981          DOI: 10.1007/s40620-014-0124-6

Source DB:  PubMed          Journal:  J Nephrol        ISSN: 1121-8428            Impact factor:   3.902


  20 in total

1.  K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2003-10       Impact factor: 8.860

2.  Circadian changes in plasma phosphate concentration, urinary phosphate excretion, and cellular phosphate shifts.

Authors:  G J Kemp; A Blumsohn; B W Morris
Journal:  Clin Chem       Date:  1992-03       Impact factor: 8.327

Review 3.  Ergocalciferol and cholecalciferol in CKD.

Authors:  Sagar U Nigwekar; Ishir Bhan; Ravi Thadhani
Journal:  Am J Kidney Dis       Date:  2012-05-05       Impact factor: 8.860

4.  The Relation of Insulin to Phosphate Metabolism.

Authors:  W C Stadie
Journal:  Yale J Biol Med       Date:  1944-05

5.  Dietary intake of phosphorus modulates the circadian rhythm in serum concentration of phosphorus. Implications for the renal production of 1,25-dihydroxyvitamin D.

Authors:  A A Portale; B P Halloran; R C Morris
Journal:  J Clin Invest       Date:  1987-10       Impact factor: 14.808

6.  Phosphorus binders and survival on hemodialysis.

Authors:  Tamara Isakova; Orlando M Gutiérrez; Yuchiao Chang; Anand Shah; Hector Tamez; Kelsey Smith; Ravi Thadhani; Myles Wolf
Journal:  J Am Soc Nephrol       Date:  2008-12-17       Impact factor: 10.121

7.  High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients.

Authors:  Guillaume Jean; Jean-Claude Terrat; Thierry Vanel; Jean-Marc Hurot; Christie Lorriaux; Brice Mayor; Charles Chazot
Journal:  Nephrol Dial Transplant       Date:  2009-04-25       Impact factor: 5.992

8.  Prevalence of 25-OH vitamin D deficiency in a population of hemodialysis patients and efficacy of an oral ergocalciferol supplementation regimen.

Authors:  Anna Porter; Cheryl Gilmartin; Usasiri Srisakul; Jose Arruda; Sanjeev Akkina
Journal:  Am J Nephrol       Date:  2013-05-30       Impact factor: 3.754

9.  Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population.

Authors:  Jürgen Floege; Joseph Kim; Elizabeth Ireland; Charles Chazot; Tilman Drueke; Angel de Francisco; Florian Kronenberg; Daniele Marcelli; Jutta Passlick-Deetjen; Guntram Schernthaner; Bruno Fouqueray; David C Wheeler
Journal:  Nephrol Dial Transplant       Date:  2010-04-25       Impact factor: 5.992

10.  Circadian rhythm of salivary cortisol, plasma cortisol, and plasma ACTH in end-stage renal disease.

Authors:  Hershel Raff; Hariprasad Trivedi
Journal:  Endocr Connect       Date:  2012-11-19       Impact factor: 3.335

View more
  12 in total

1.  Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial.

Authors:  Geoffrey A Block; David P Rosenbaum; Andrew Yan; Glenn M Chertow
Journal:  J Am Soc Nephrol       Date:  2019-03-07       Impact factor: 10.121

Review 2.  A Systematic Review of the Circadian Rhythm of Bone Markers in Blood.

Authors:  Sarah Seberg Diemar; Stig Søgaard Dahl; Anders Sode West; Sofie Amalie Simonsen; Helle Klingenberg Iversen; Niklas Rye Jørgensen
Journal:  Calcif Tissue Int       Date:  2022-03-19       Impact factor: 4.333

3.  Calcium, phosphate, and PTH circadian rhythm in peritoneal dialysis: seven cases and something to think about.

Authors:  Francesca K Martino; Fiammetta Zanetti; Giulia Fanton; Gianpaolo Amici
Journal:  J Nephrol       Date:  2022-03-29       Impact factor: 4.393

Review 4.  Pharmacological Management of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.

Authors:  S N Salam; A Khwaja; M E Wilkie
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546

Review 5.  The role of phosphate in kidney disease.

Authors:  Marc G Vervloet; Siren Sezer; Ziad A Massy; Lina Johansson; Mario Cozzolino; Denis Fouque
Journal:  Nat Rev Nephrol       Date:  2016-11-21       Impact factor: 28.314

6.  A potential kidney-bone axis involved in the rapid minute-to-minute regulation of plasma Ca2+.

Authors:  Anders Nordholm; Maria L Mace; Eva Gravesen; Klaus Olgaard; Ewa Lewin
Journal:  BMC Nephrol       Date:  2015-03-15       Impact factor: 2.388

Review 7.  Strategies for Phosphate Control in Patients With CKD.

Authors:  Fellype Carvalho Barreto; Daniela Veit Barreto; Ziad A Massy; Tilman B Drüeke
Journal:  Kidney Int Rep       Date:  2019-06-20

8.  KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention and Prevention of Chronic Kidney Disease-Mineral and Bone Disorder (CKDMBD): Indian Commentary.

Authors:  Anna T Valson; Manisha Sahay; Narayan Prasad; Sanjay Kumar Agarwal; Santosh Varughese; Sishir Gang
Journal:  Indian J Nephrol       Date:  2020-07-30

9.  The Effect of Moderate Dietary Protein and Phosphate Restriction on Calcium-Phosphate Homeostasis in Healthy Older Cats.

Authors:  R F Geddes; V Biourge; Y Chang; H M Syme; J Elliott
Journal:  J Vet Intern Med       Date:  2016-08-16       Impact factor: 3.333

10.  Development of experimental chronic kidney disease and vascular calcification alters diurnal variation of phosphate and its hormonal regulators.

Authors:  Bruno A Svajger; Justin L H Riddoch; Cynthia M Pruss; Kimberly J Laverty; Emilie Ward; Rachel M Holden; Michael A Adams
Journal:  Physiol Rep       Date:  2020-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.